Global collaboration is the cornerstone of scientific advancement.
Frontiers in Pharmacology has organized a series of special edition Research Topics, with the goal of highlighting the latest advancements in Renal Pharmacology across the globe, showcasing the academic excellence and high-quality work of internationally recognized researchers.
These collections aim to shed light on the recent progress made across the entire breadth of the Renal Pharmacology field and reflect on the future challenges researchers face across borders.
This Research Topic welcomes original research and review articles from Central & South America covering, but not limited to, the latest and most significant discoveries on:
• Novel therapeutic strategies targeting hemodynamic, metabolic, and inflammatory events in renal diseases;
• Gut microbiota-based therapies and kidney diseases;
• Targeting the metabolism of immune and non-immune kidney cells to slow the progression of nephropathies;
• Mechanisms of action for novel and existing drugs used to reduce lipotoxicity in kidney diseases.
Please inform the
Editorial Office once you are prepared to submit.
Global collaboration is the cornerstone of scientific advancement.
Frontiers in Pharmacology has organized a series of special edition Research Topics, with the goal of highlighting the latest advancements in Renal Pharmacology across the globe, showcasing the academic excellence and high-quality work of internationally recognized researchers.
These collections aim to shed light on the recent progress made across the entire breadth of the Renal Pharmacology field and reflect on the future challenges researchers face across borders.
This Research Topic welcomes original research and review articles from Central & South America covering, but not limited to, the latest and most significant discoveries on:
• Novel therapeutic strategies targeting hemodynamic, metabolic, and inflammatory events in renal diseases;
• Gut microbiota-based therapies and kidney diseases;
• Targeting the metabolism of immune and non-immune kidney cells to slow the progression of nephropathies;
• Mechanisms of action for novel and existing drugs used to reduce lipotoxicity in kidney diseases.
Please inform the
Editorial Office once you are prepared to submit.
